Stocks · News reference
Arcadia Biosciences Q2 EPS $(2.09) Up From $(3.26) YoY, Sales $1.443M Down From $1.455M YoY
Arcadia Biosciences (NASDAQ:RKDA) reported quarterly losses of $(2.09) per share. This is a 35.89 percent increase over losses of $(3.26) per share from the same period last year. The company reported $1.443 million in
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Why GlucoTrack Shares Are Trading Higher By Around 118%; Here Are 20 Stocks Moving Premarket
GlucoTrack surged 117.7% premarket after Lokahi Therapeutics signed its first external partnership; other stocks saw notable gains and losses.
8-K filing — Arcadia Biosciences, Inc. (RKDA)
Filed: 2026-09-15 AccNo: 0001193125-26-391780 Size: 788 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.07: Submission of Matters to a Vote of Security Holders Item 9.01: Financial Statements and Exhibits
Arcadia Biosciences shares are trading higher after the company reported a year-over-year increase in its Q2 EPS results.